腎臓がん治療薬市場：タイプ別、薬理学的クラス別、治療クラス別-2023-2030年の世界予測

腎臓がん治療薬の世界市場は大きく成長すると予測され、2023年には58億213万米ドル、CAGRは5.95%と予測され、2030年には87億1,012万米ドルに達する見込みです。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の腎臓がん治療薬市場を評価するために不可欠です。事業戦略や製品満足度などの主要指標を検証することで、ベンダーの包括的な評価を提供し、ユーザーが特定のニーズに基づいて情報に基づいた意思決定を行えるようにします。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.腎臓がん治療薬の世界市場規模および予測は？

2.予測期間中、世界の腎臓がん治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.腎臓がん治療薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.腎臓がん治療薬の世界市場における競争戦略は？

5.腎臓がん治療薬の世界市場における技術動向と規制の枠組みは？

6.腎臓がん治療薬の世界市場における主要ベンダーの市場シェアは？

7.腎臓がん治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がんに苦しむ人の数の急増
    • 高血圧や糖尿病を抱える高齢者人口の増加
    • 喫煙、飲酒、加工食品の摂取など、ライフスタイルの変化の増加
  • 抑制要因
    • 治療に伴う合併症のリスク
  • 機会
    • 新薬の入手可能性と強力なパイプラインの存在
    • メーカー間の連携による研究開発投資の増加
  • 課題
    • 厳格な規制政策
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ
  • パイプライン分析

第6章 腎臓がん治療薬市場：タイプ別

• 嫌色素性者
• クリアセル
• 集合ダクト
• 腫瘍細胞性
• 乳頭状

第7章 腎臓がん治療薬市場薬理クラス別

• 血管新生阻害剤
• サイトカイン免疫療法
• モノクローナル抗体
• MTOR阻害剤

第8章 腎臓がん治療薬市場セラピークラス別

• 免疫療法
• 標的療法

第9章 南北アメリカの腎臓がん治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の腎臓がん治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの腎臓がん治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第13章 掲載企業一覧

第14章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. KIDNEY CANCER DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. KIDNEY CANCER DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. KIDNEY CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
• FIGURE 5. KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2022 VS 2030 (%)
• FIGURE 6. KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2022 VS 2030 (%)
• FIGURE 7. KIDNEY CANCER DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 8. KIDNEY CANCER DRUGS MARKET DYNAMICS
• FIGURE 9. KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. KIDNEY CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 17. KIDNEY CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. KIDNEY CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. KIDNEY CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 5. KIDNEY CANCER DRUGS MARKET SIZE, BY CHROMOPHOBE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. KIDNEY CANCER DRUGS MARKET SIZE, BY CLEAR CELL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. KIDNEY CANCER DRUGS MARKET SIZE, BY COLLECTING DUCT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. KIDNEY CANCER DRUGS MARKET SIZE, BY ONCOCYTIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. KIDNEY CANCER DRUGS MARKET SIZE, BY PAPILLARY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 11. KIDNEY CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. KIDNEY CANCER DRUGS MARKET SIZE, BY CYTOKINE IMMUNOTHERAPY , BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. KIDNEY CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. KIDNEY CANCER DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 16. KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 28. CANADA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 30. CANADA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 45. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 47. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 48. INDIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 50. INDIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 100. ITALY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 102. ITALY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 112. POLAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 114. POLAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 115. QATAR KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 117. QATAR KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM KIDNEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM KIDNEY CANCER DRUGS MARKET SIZE, BY PHARMACOLOGIC CLASS, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM KIDNEY CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 145. KIDNEY CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 146. KIDNEY CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 147. KIDNEY CANCER DRUGS MARKET LICENSE & PRICING

The Global Kidney Cancer Drugs Market is forecasted to grow significantly, with a projected USD 5,802.13 million in 2023 at a CAGR of 5.95% and expected to reach a staggering USD 8,710.12 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Kidney Cancer Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Kidney Cancer Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Chromophobe, Clear Cell, Collecting Duct, Oncocytic, and Papillary. The Collecting Duct is projected to witness significant market share during forecast period.

Based on Pharmacologic Class, market is studied across Angiogenesis Inhibitors, Cytokine Immunotherapy, Monoclonal Antibodies, and MTOR Inhibitors. The Monoclonal Antibodies is projected to witness significant market share during forecast period.

Based on Therapeutic Class, market is studied across Immunotherapy and Targeted Therapy. The Targeted Therapy is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Kidney Cancer Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Kidney Cancer Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Kidney Cancer Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Kidney Cancer Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Kidney Cancer Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Kidney Cancer Drugs Market?

6. What is the market share of the leading vendors in the Global Kidney Cancer Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Kidney Cancer Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Kidney Cancer Drugs Market, by Type, 2022 vs 2030
• 4.3. Kidney Cancer Drugs Market, by Pharmacologic Class, 2022 vs 2030
• 4.4. Kidney Cancer Drugs Market, by Therapeutic Class, 2022 vs 2030
• 4.5. Kidney Cancer Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Proliferation in the number of people suffering from cancer
    • 5.1.1.2. Growing geriatric population with hypertension and diabetes
    • 5.1.1.3. Increasing lifestyle changes including smoking, drinking, and consumption of processed food
  • 5.1.2. Restraints
    • 5.1.2.1. Risk of complications associated with treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Availability of novel drugs and the presence of a strong pipeline
    • 5.1.3.2. Increasing research and development investment coupled with collaborations among manufacturers
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory policies
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization
  • 5.9.1. Pipeline Analysis

6. Kidney Cancer Drugs Market, by Type

• 6.1. Introduction
• 6.2. Chromophobe
• 6.3. Clear Cell
• 6.4. Collecting Duct
• 6.5. Oncocytic
• 6.6. Papillary

7. Kidney Cancer Drugs Market, by Pharmacologic Class

• 7.1. Introduction
• 7.2. Angiogenesis Inhibitors
• 7.3. Cytokine Immunotherapy
• 7.4. Monoclonal Antibodies
• 7.5. MTOR Inhibitors

8. Kidney Cancer Drugs Market, by Therapeutic Class

• 8.1. Introduction
• 8.2. Immunotherapy
• 8.3. Targeted Therapy

9. Americas Kidney Cancer Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Kidney Cancer Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Kidney Cancer Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing